8-K: Syndax Announces Positive Topline Results for Revumenib in Relapsed or Refractory mNPM1 AML

Syndax Pharmaceuticals reports positive topline results from the AUGMENT-101 trial for revumenib in relapsed or refractory mutant NPM1 acute myeloid leukemia, meeting its primary endpoint.

Summary

• Syndax Pharmaceuticals announced positive topline results from the Phase 2 portion of the AUGMENT-101 trial for revumenib in patients with relapsed or refractory mutant NPM1 (mNPM1) acute myeloid leukemia (AML).
• The trial met its primary endpoint with a complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 23% (15 out of 64 patients).
• The overall response rate (ORR) was 47% (30 out of 64 patients) in a heavily pre-treated population, with 75% having prior venetoclax exposure.
• The median duration of CR/CRh responses was 4.7 months.
• 64% of patients who achieved CR/CRh were minimal residual disease (MRD) negative.
• The safety profile was favorable, with only 5% of patients discontinuing treatment due to treatment-related adverse events.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, with a high overall response rate and a favorable safety profile. The company is also on track for regulatory submissions, indicating a strong outlook for the drug's development. The sentiment is very positive.

Positives

• The trial achieved a statistically significant primary endpoint with a CR/CRh rate of 23%.
• The overall response rate of 47% is promising in a heavily pre-treated patient population.
• The safety profile of revumenib was favorable, with a low discontinuation rate due to adverse events.
• The results show consistency of revumenib's clinical profile across different treatment settings.
• The company is on track to submit an sNDA for mNPM1 AML in the first half of 2025.

Negatives

• The median duration of CR/CRh responses was 4.7 months, which may be considered relatively short.
• Treatment-related adverse events of Grade 3 or higher included QTc prolongation (21%), anemia (14%), febrile neutropenia (13%), differentiation syndrome (13%), and decreased platelet count (11%).

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• There are risks associated with clinical trial outcomes, regulatory approvals, and market acceptance of the product.
• The company faces competition from other pharmaceutical companies developing cancer therapies.
• Unexpected safety or efficacy data observed during clinical trials could impact the approval process.

Future Outlook

Syndax expects to receive FDA approval for revumenib in R/R KMT2Ar acute leukemia in the fourth quarter of 2024 and plans to submit an sNDA for R/R mNPM1 AML in the first half of 2025. The company also plans to initiate a pivotal combination trial by year-end 2024.

Management Comments

• Michael A. Metzger, Chief Executive Officer of Syndax, stated that the positive pivotal data in R/R mNPM1 AML patients treated with revumenib has shown compelling and notably consistent results across treatment settings.
• Eytan M. Stein, M.D., Chief, Leukemia Service, Memorial Sloan Kettering Cancer Center, noted that the positive results for revumenib in this heavily pre-treated population are very encouraging.

Industry Context

The announcement is significant as it addresses a critical unmet need in relapsed or refractory mNPM1 AML, a challenging disease with limited treatment options. The positive results position Syndax as a key player in the development of targeted therapies for AML.

Comparison to Industry Standards

• The 23% CR/CRh rate is a notable result in the context of relapsed/refractory AML, where treatment outcomes are generally poor. For example, traditional chemotherapy regimens often yield lower response rates in this setting.
• The 47% ORR is also competitive, especially considering the heavily pre-treated nature of the patient population, with 75% having prior venetoclax exposure. This suggests that revumenib may offer a valuable option for patients who have failed other therapies.
• While direct comparisons are difficult without head-to-head trials, the results appear to be in line with or better than some other targeted therapies in development for AML, such as FLT3 inhibitors in FLT3-mutated AML. However, the specific patient populations and trial designs vary, making direct comparisons challenging.
• The low discontinuation rate due to treatment-related adverse events (5%) is also a positive sign, suggesting that revumenib is relatively well-tolerated compared to some other AML treatments.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the potential for regulatory approvals.
• Patients with relapsed or refractory mNPM1 AML may benefit from a new treatment option.
• Employees of Syndax may be motivated by the positive progress of the company's pipeline.
• The results could positively impact the company's relationships with collaborators and investors.

Next Steps

• Syndax will present data at the 66th American Society of Hematology (ASH) Annual Meeting in December 2024.
• The company plans to initiate a pivotal combination trial with venetoclax/azacitidine by year-end 2024.
• Syndax expects to publish pivotal AUGMENT-101 results and present them at a medical conference in the first half of 2025.
• The company will submit a supplemental NDA (sNDA) for treatment of R/R mNPM1 AML in the first half of 2025.

Key Dates

Keywords

revumenib, mNPM1, AML, acute myeloid leukemia, AUGMENT-101, menin inhibitor, KMT2Ar, cancer therapy, hematology, clinical trial